Impel Pharmaceuticals Gross Profit

Impel Pharmaceuticals (IMPL) currently reports a gross profit of $11M as of September 2023. That compares with $3.5M in the prior-year period — up 215.1% year over year. That is below the Healthcare sector average of $65B. Use the charts on this page to explore Impel Pharmaceuticals's gross profit history and peer comparisons.

Impel Pharmaceuticals's gross profit increased from $3.5M to $11M — a 215.1% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Impel Pharmaceuticals's gross profit of $11M is lower than the Healthcare sector average of $65B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Impel Pharmaceuticals reported $11M in gross profit as of September 2023. That compares with $3.5M in the prior-year period — up 215.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $11M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $65B. From there, open related valuation or income-statement pages for Impel Pharmaceuticals, and consider following IMPL for alerts when major investors trade the stock.